Long‐term edaravone efficacy in amyotrophic lateral sclerosis: Post‐hoc analyses of Study 19 (MCI186‐19)
Abstract Background In a Phase 3 study, amyotrophic lateral sclerosis (ALS) patients
experienced significantly less physical functional decline with 24‐week edaravone vs …
experienced significantly less physical functional decline with 24‐week edaravone vs …
[HTML][HTML] Long‐term edaravone efficacy in amyotrophic lateral sclerosis: Post‐hoc analyses of Study 19 (MCI186‐19)
J Shefner, T Heiman‐Patterson, EP Pioro… - Muscle & …, 2020 - ncbi.nlm.nih.gov
Background In a Phase 3 study, amyotrophic lateral sclerosis (ALS) patients experienced
significantly less physical functional decline with 24‐week edaravone vs placebo, followed …
significantly less physical functional decline with 24‐week edaravone vs placebo, followed …
Long-term edaravone efficacy in amyotrophic lateral sclerosis: Post-hoc analyses of Study 19 (MCI186-19)
J Shefner, T Heiman-Patterson, EP Pioro… - Muscle and …, 2020 - scholars.northwestern.edu
Background: In a Phase 3 study, amyotrophic lateral sclerosis (ALS) patients experienced
significantly less physical functional decline with 24-week edaravone vs placebo, followed …
significantly less physical functional decline with 24-week edaravone vs placebo, followed …
Long‐term edaravone efficacy in amyotrophic lateral sclerosis: Post‐hoc analyses of Study 19 (MCI186‐19)
J Shefner, T Heiman‐Patterson, EP Pioro… - Muscle & Nerve, 2019 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: sec>< jats: title> Background</jats: title>< jats: p>
In a Phase 3 study, amyotrophic lateral sclerosis (ALS) patients experienced significantly …
In a Phase 3 study, amyotrophic lateral sclerosis (ALS) patients experienced significantly …
[PDF][PDF] Long-term edaravone efficacy in amyotrophic lateral sclerosis: Post-hoc analyses of Study 19 (MCI186-19)
2019 - academia.edu
Abstract Background: In a Phase 3 study, amyotrophic lateral sclerosis (ALS) patients
experienced significantly less physical functional decline with 24-week edaravone vs …
experienced significantly less physical functional decline with 24-week edaravone vs …
Long-term edaravone efficacy in amyotrophic lateral sclerosis: Post-hoc analyses of Study 19 (MCI186-19)
J Shefner, T Heiman-Patterson, EP Pioro… - Muscle & …, 2020 - pubmed.ncbi.nlm.nih.gov
Background In a Phase 3 study, amyotrophic lateral sclerosis (ALS) patients experienced
significantly less physical functional decline with 24-week edaravone vs placebo, followed …
significantly less physical functional decline with 24-week edaravone vs placebo, followed …
Long-term edaravone efficacy in amyotrophic lateral sclerosis: Post-hoc analyses of Study 19 (MCI186-19).
J Shefner, T Heiman-Patterson, EP Pioro… - Muscle & …, 2019 - europepmc.org
Background In a Phase 3 study, amyotrophic lateral sclerosis (ALS) patients experienced
significantly less physical functional decline with 24-week edaravone vs placebo, followed …
significantly less physical functional decline with 24-week edaravone vs placebo, followed …
Long-term edaravone efficacy in amyotrophic lateral sclerosis: Post-hoc analyses of Study 19 (MCI186-19).
J Shefner, T Heiman-Patterson, EP Pioro… - Muscle & …, 2019 - europepmc.org
Background In a Phase 3 study, amyotrophic lateral sclerosis (ALS) patients experienced
significantly less physical functional decline with 24-week edaravone vs placebo, followed …
significantly less physical functional decline with 24-week edaravone vs placebo, followed …